22nd Jul 2015 11:50
LONDON (Alliance News) - Pharmaceutical company Shire PLC said Wednesday it has seen positive top-line results from its study of vyvanse in adults with moderate to severe binge eating disorder.
The objective of the study was to evaluate the efficacy of vyvanse against a placebo. During the term of the study vyvanse demonstrated superiority over the placebo, and at the conclusion of the study the group of patients on vyvanse has a significantly lower proportion of relapse compared to the placebo group.
FTSE 100-listed Shire plans to use these results, along with findings from a seperate 12 month open-label safety extension study to submit a new drug application to the US Food and Drug Administration before the end of the year.
Shares in Shire are trading up 0.6% at 5,465.00 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire